Lecture I:

Chairman: F. Lo Coco

12:40

Opening ceremony

G. Leone

13:00

Senescence and cancer

P.G. Pelicci

13:20

Therapy-related myeloid neoplasm: who really has it?

R.P. Gale

Age-related clonal hematopoiesis:

Chairmen: A. Cuneo, D.G. Tenen

13:40

Clonal hematopoiesis, isolated cytopenias and differences with myelodysplastic syndromes

P. Fenaux

14:00

Selected Abstract:
Clonal evolution in therapy-related neoplasms

E. Fabiani

GILEAD Sponsored Lecture:

Chairman: M.A. Sanz

14:45

Invasive fungal complications in secondary leukemia

L. Pagano

Biology of therapy-related myeloid neoplasms:

Chairmen: M.M. Le Beau, C. Nervi

15:45

Mutational landscape of therapy-related versus other secondary leukemias

M.J. Walter

16:20

Molecular analysis of del(5q) t-MN and identification of haploinsufficient tumor suppressor genes on 5q

M.M. Le Beau

17:00

Selected Abstract:
Baseline predictors of mortality in patients with relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine or placebo plus cytarabine in the phase 3 valor study

A.M. Carella

17:40

Selected Abstract:
The ELN risk classification has prognostic relevance also in elderly patients with secondary acute myeloid leukemia and may support treatment decisions. A retrospective multicentric study of the reteematologica lombarda (REL)

M. Farina

Epidemiology, cytogenetic and clinical features of t-MN

Chairmen: S. Amadori, G. Specchia

9:00

Epidemiology of t-MN: an evolving scenario?

S.M. Ramadan

10:00

Differences between therapy-related and secondary leukemias

R.A. Larson

Lecture II:

Chairman: M. Cazzola

11:00

WHO 2016 classification of AML

B. Falini

Secondary leukemias and primary malignancies:

Chairmen: M. Baccarani, V. De Stefano

11:30

Myeloproliferative disorders

T. Barbui

11:45

Lymphoproliferative disorders

S. Hohaus

12:15

Strategies to minimize the occurrence of t-MN: the paradigm of childhood ALL

A. Biondi

12:30

Selected Abstract:
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with atra and chemotherapy

L. Iaccarino

CELGENE Sponsored Lecture:

Chairman: A. Tafuri

13:00

Treatment of low-blast count AML

M.T. Voso

Leukemogenesis according to the type of exposure:

Chairmen: D. Grimwade, F. Pane

14:30

Mitoxantrone

S.K. Hasan

15:00

Radiotherapy

R.A. Larson

15:20

A-bombs and environmental exposures

R.P. Gale

15:40

- The role of embryonic stem (ES) cell factor SALL4 in MDS/AML

L. Chai

TEVA Sponsored Lecture:

Chairman: G. Avvisati

16:00

Acute promyelocytic leukemia as a second tumor

F. Lo Coco

Lecture III:

Chairman: G. Cimino

9:00

Regulation of DNA methylation by RNA

D.G. Tenen

Natural history of t-MN and treatment:

Chairmen: W. Arcese, S. Sica

9:30

Differential treatment approaches for therapy-related acute leukemias

A. Venditti

10:00

Role of allogeneic transplantation

A. Rambaldi

10:30

Clinical effect of somatic mutations in t-MN treated with allogeneic stem cell transplantation

M.G. Della Porta

11:00

Selected Abstract:
Monocentric observational study on secondary haematological neoplasms (t-HN) treated with allogeneic hematopoietic stem cell transplantation S. Sica

S. Sica